| 货号 | 18870-10mg |
| 描述 | Lennox-Gastaut syndrome (LGS) is a severe pediatric epilepsy syndrome characterized by multiple seizure types.1 Rufinamide is a triazole derivative that serves as the active ingredient in a formulation that is used in adjunctive treatment of LGS to limit seizure frequency.1,2 The mechanism of action of rufinamide is unclear, although it is thought to limit the frequency of sodium-dependent neuronal action potentials.3,4 |
| 别名 | CGP 33101;RUF 331; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Al-Banji, M.H.,Zahr, D., and Jan, M.M. Lennox-Gastaut syndrome. Management update. Neuroscience (Riyadh) 20(3), 207-212 (2015). 2.Aneja, S., and Sharma, S. Newer anti-epileptic drugs. Indian Pediatr. 50(11), 1033-1040 (2013). 3.Luszczki, J.J. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports 6, 197-216 (2009). 4.Rogawski, M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Research 69(3), 273-294 (2006). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 238.2 |
| 分子式 | C10H8F2N4O |
| CAS号 | 106308-44-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |